Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Retained Earnings: 2010-2024

Historic Retained Earnings for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to -$403.5 million.

  • Lineage Cell Therapeutics' Retained Earnings fell 16.91% to -$467.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$467.8 million, marking a year-over-year decrease of 16.91%. This contributed to the annual value of -$403.5 million for FY2024, which is 4.84% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Retained Earnings stood at -$403.5 million, which was down 4.84% from -$384.9 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Retained Earnings ranged from a high of -$294.1 million in FY2020 and a low of -$403.5 million during FY2024.
  • Its 3-year average for Retained Earnings is -$383.9 million, with a median of -$384.9 million in 2023.
  • Data for Lineage Cell Therapeutics' Retained Earnings shows a maximum YoY decreased of 14.63% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Retained Earnings stood at -$294.1 million in 2020, then decreased by 14.63% to -$337.1 million in 2021, then decreased by 7.79% to -$363.4 million in 2022, then dropped by 5.91% to -$384.9 million in 2023, then declined by 4.84% to -$403.5 million in 2024.